Search Page

1

Cite

Share

Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study.

Taucher C, Kollaritsch H, Dubischar KL. Taucher C, et al. Among authors: dubischar kl. Vaccine. 2019 May 1;37(19):2529-2531. doi: 10.1016/j.vaccine.2019.03.030. Epub 2019 Apr 5. Vaccine. 2019. PMID: 30962094 Free article.

Cite

Share

2

Cite

Share

Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.

Bézay N, Ayad A, Dubischar K, Firbas C, Hochreiter R, Kiermayr S, Kiss I, Pinl F, Jilma B, Westritschnig K. Bézay N, et al. Vaccine. 2016 May 17;34(23):2585-92. doi: 10.1016/j.vaccine.2016.03.098. Epub 2016 Apr 11. Vaccine. 2016. PMID: 27079932 Clinical Trial.

Cite

Share

3

Cite

Share

Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study.

Cramer JP, Dubischar K, Eder S, Burchard GD, Jelinek T, Jilma B, Kollaritsch H, Reisinger E, Westritschnig K. Cramer JP, et al. Vaccine. 2016 Aug 31;34(38):4579-4585. doi: 10.1016/j.vaccine.2016.07.029. Epub 2016 Jul 25. Vaccine. 2016. PMID: 27460550 Clinical Trial.

Cite

Share

4

Cite

Share

Immunogenicity of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children From a Japanese Encephalitis Virus-endemic Region.

Dubischar KL, Kadlecek V, Sablan JB, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Kiermayr S, Spruth M, Westritschnig K. Dubischar KL, et al. Pediatr Infect Dis J. 2017 Sep;36(9):898-904. doi: 10.1097/INF.0000000000001615. Pediatr Infect Dis J. 2017. PMID: 28430748 Clinical Trial.

Cite

Share

5

Cite

Share

Safety of the Inactivated Japanese Encephalitis Virus Vaccine IXIARO in Children: An Open-label, Randomized, Active-controlled, Phase 3 Study.

Dubischar KL, Kadlecek V, Sablan B Jr, Borja-Tabora CF, Gatchalian S, Eder-Lingelbach S, Mueller Z, Westritschnig K. Dubischar KL, et al. Pediatr Infect Dis J. 2017 Sep;36(9):889-897. doi: 10.1097/INF.0000000000001623. Pediatr Infect Dis J. 2017. PMID: 28441266 Clinical Trial.

Cite

Share

6

Cite

Share

Safety and immunogenicity of an inactivated Vero cell_derived Japanese encephalitis vaccine (IXIARO^®, JESPECT^®) in a pediatric population in JE non-endemic countries: An uncontrolled, open-label phase 3 study.

Jelinek T, Cromer MA, Cramer JP, Mills DJ, Lessans K, Gherardin AW, Barnett ED, Hagmann SHF, Askling HH, Kiermayr S, Kadlecek V, Eder-Lingelbach S, Taucher C, Dubischar KL. Jelinek T, et al. Among authors: dubischar kl. Travel Med Infect Dis. 2018 Mar-Apr;22:18-24. doi: 10.1016/j.tmaid.2018.03.003. Epub 2018 Mar 13. Travel Med Infect Dis. 2018. PMID: 29549036 Free article. Clinical Trial.

Cite

Share

7

Cite

Share

Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose.

Kadlecek V, Borja-Tabora CF, Eder-Lingelbach S, Gatchalian S, Kiermayr S, Sablan B Jr, Kundi M, Taucher C, Dubischar KL. Kadlecek V, et al. Among authors: dubischar kl. Pediatr Infect Dis J. 2018 Sep;37(9):e233-e240. doi: 10.1097/INF.0000000000002124. Pediatr Infect Dis J. 2018. PMID: 29912844 Clinical Trial.

Cite

Share

8

Cite

Share

Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study.

Taucher C, Barnett ED, Cramer JP, Eder-Lingelbach S, Jelinek T, Kadlecek V, Kiermayr S, Mills DJ, Pandis D, Reiner D, Dubischar KL. Taucher C, et al. Among authors: dubischar kl. Travel Med Infect Dis. 2020 Mar-Apr;34:101616. doi: 10.1016/j.tmaid.2020.101616. Epub 2020 Mar 7. Travel Med Infect Dis. 2020. PMID: 32156630 Free article. Clinical Trial.

Cite

Share

9

Cite

Share

Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.

Wressnigg N, Hochreiter R, Zoihsl O, Fritzer A, Bézay N, Klingler A, Lingnau K, Schneider M, Lundberg U, Meinke A, Larcher-Senn J, Čorbic-Ramljak I, Eder-Lingelbach S, Dubischar K, Bender W. Wressnigg N, et al. Lancet Infect Dis. 2020 Oct;20(10):1193-1203. doi: 10.1016/S1473-3099(20)30238-3. Epub 2020 Jun 1. Lancet Infect Dis. 2020. PMID: 32497524 Clinical Trial.

Cite

Share